In Europe, an etanercept biosimilar is getting closer to being approved to treat RA and more, and in the U.S., an application for an adalimumab biosimilar has been submitted for FDA approval. Also, an analysis of methotrexate use in the U.S. shows that therapy may actually be underused for RA…
Starting your own rheumatology practice is daunting, and it’s easy to focus on the medical side and neglect the business side of a practice. Here are five important considerations that could help a new practice thrive…
To ensure adequate and appropriate reimbursement, rheumatologists must provide detailed information about their services to the people advocating on their behalf. With the proper information, advocates can then do the work necessary to secure the appropriate values for these services. These advocates are members of the Relative Value Update Committee (RUC), a volunteer committee of…
A new study from Stockholm, Sweden, strengthens the link between the lungs and anti-citrullinated protein antibody (ACPA)–positive RA. After analyzing the bronchial tissue of untreated patients with early RA, researchers found the patients’ lungs had signs of immune cell accumulation and activation…
(Reuters Health)—Whether surgical trainees should be able to work long shifts is a matter of fierce debate, and the methods of a controversial study aimed at answering that question were outlined in a top surgical journal. The results won’t be available until February. In the meantime, critics of the study say it exposed residents and…
Despite the relative novelty of the human microbiome as an area of study, a substantial body of evidence has accumulated addressing its potential involvement in the pathogenesis of rheumatic disease. This review article explores the available data in animal and human studies, focusing on the role of the intestinal microbiome in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and the spondyloarthritidies (SpA)…
Dr. Soumya Raychaudhuri of the Harvard Medical School, Boston, discusses how his interest in math led him to the study of bioinformatics in rheumatology. He addresses how big data can play a role in clinical rheumatology in years to come…
SAN FRANCISCO—Two hundred years ago, physicians knew nothing about what caused various forms of arthritis. Today, we have more clues about what may trigger rheumatic diseases, but still can’t pinpoint the culprits that set scores of inflammatory conditions in motion. Researchers discussed some of the background and recent findings that point to what immunologists call…
NEW YORK (Reuters)—The U.S. government signed up 8.2 million people for health insurance through the HealthCare.gov website through Dec. 19, including 2.1 million people from the insurers’ most sought-after demographic: those aged under 35, according to the top health official. That compares with the 6.4 million people who signed up or were automatically signed up…
NEW YORK (Reuters)—A new class of blood thinners that competes with widely used warfarin should get a boost next year when an “antidote” that can reverse the medications’ effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson & Johnson, and…